

Table 2. Outcomes of four real-world studies of dabrafenib (150 mg twice daily) plus trametinib (2 mg daily) to treat ATC

	Median follow up	Treatment cycles (range)	ORR (CR + PR)	CR	PR	DOR	PFS	OS
Lorimer et al. 2023 n=17 (9 men; mean age 68 years; UK)	12 months (range 3–43)	4.5 (range 1–22)	82%	12%	70%	NR	4.7 months (95% CI 1.4 to 7.8 months)	6.9 months (95% CI 2.46 to ULNR)
Iyer et al. 2019 n=6 (USA)	11.8 months	NR	50%	0%	50%	8.3 weeks (range 1.5 to 34.5)	5.2 months (95% CI 3.7 months to ULNR)	9.3 months (95% CI 5.7 to ULNR)
Wang et al. 2019 n=6 (2 men, median age 59 years; USA)	15 months (range 6.4 to 25.2)	NR	100%	0%	100%	NR	NR	NR
Bueno et al. 2023 n=5 (3 men; median age 70 years; Argentina)	5 months (range 1.5 to 23)	NR	80%	40%	40%	20 weeks (range 16 to 92 weeks; 95% CI 15.7 to 24.3).	NR	NR

ATC: anaplastic thyroid cancer; CI: confidence interval; CR: complete response; DOR: duration of response (or clinical benefit); NR: not reported; ORR: objective response rate; PFS: progression-free survival; PR: partial response; OS: overall survival; ULNR: upper limit not reached